SG146687A1 - Drug containing (2r)-2-propyloctanoic acid as the active ingredient - Google Patents

Drug containing (2r)-2-propyloctanoic acid as the active ingredient

Info

Publication number
SG146687A1
SG146687A1 SG200807282-9A SG2008072829A SG146687A1 SG 146687 A1 SG146687 A1 SG 146687A1 SG 2008072829 A SG2008072829 A SG 2008072829A SG 146687 A1 SG146687 A1 SG 146687A1
Authority
SG
Singapore
Prior art keywords
active ingredient
propyloctanoic acid
medicament
drug containing
acid
Prior art date
Application number
SG200807282-9A
Other languages
English (en)
Inventor
Masao Sudoh
Seiichi Tanikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of SG146687A1 publication Critical patent/SG146687A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
SG200807282-9A 2003-10-03 2004-10-01 Drug containing (2r)-2-propyloctanoic acid as the active ingredient SG146687A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003345124 2003-10-03

Publications (1)

Publication Number Publication Date
SG146687A1 true SG146687A1 (en) 2008-10-30

Family

ID=34419441

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200807282-9A SG146687A1 (en) 2003-10-03 2004-10-01 Drug containing (2r)-2-propyloctanoic acid as the active ingredient

Country Status (21)

Country Link
US (1) US8053599B2 (ko)
EP (1) EP1669065B1 (ko)
JP (1) JP4715515B2 (ko)
KR (1) KR101144553B1 (ko)
CN (1) CN1889942B (ko)
AU (1) AU2004277826B2 (ko)
BR (1) BRPI0415001A (ko)
CA (1) CA2540670A1 (ko)
EC (1) ECSP066477A (ko)
ES (1) ES2390055T3 (ko)
IL (1) IL174655A0 (ko)
IS (1) IS8430A (ko)
MA (1) MA28142A1 (ko)
MX (1) MXPA06003533A (ko)
NO (1) NO20061460L (ko)
NZ (1) NZ546231A (ko)
RU (1) RU2388467C2 (ko)
SG (1) SG146687A1 (ko)
TW (1) TW200519080A (ko)
WO (1) WO2005032536A1 (ko)
ZA (1) ZA200602690B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200613009A (en) * 2004-06-11 2006-05-01 Ono Pharmaceutical Co Capsule having chewing stability
TWI462745B (zh) * 2005-04-28 2014-12-01 Takeda Pharmaceutical 安定的乳化組成物
JP5541845B2 (ja) * 2008-03-28 2014-07-09 Ｊｃｒファーマ株式会社 アトピー性皮膚炎治療剤
CA2742659C (en) * 2008-11-04 2016-09-27 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone
KR20110083604A (ko) 2008-11-20 2011-07-20 테이코쿠 팔마 유에스에이, 인코포레이티드 피라졸론 유도체 제제
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
JP2018052861A (ja) * 2016-09-29 2018-04-05 ノーベルファーマ株式会社 ホスフェニトインナトリウム注射剤
WO2020128928A1 (en) * 2018-12-19 2020-06-25 Jafari Javid Mihan A formulation for treatment of neurodegenerative and demyelinating and neuropathic disorders and a method for preparation thereof
CN110441421B (zh) * 2019-08-02 2022-09-09 聊城高新生物技术有限公司 一种高效液相色谱法测定恩他卡朋片溶出度的方法
CN112180095B (zh) * 2020-06-04 2023-10-13 三诺生物传感股份有限公司 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法
IT202000015895A1 (it) * 2020-07-27 2022-01-27 Univ Cattolica Del Sacro Cuore L’impiego di acido arundico nella terapia della sclerosi multipla
CA3218713A1 (en) * 2021-05-26 2022-12-01 Daewoong Pharmaceutical Co., Ltd. Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
CN113341019A (zh) * 2021-06-09 2021-09-03 江西省药品检验检测研究院 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0632008T3 (da) * 1993-06-01 1998-09-23 Ono Pharmaceutical Co Pentansyrederivater
JPH0782146A (ja) * 1993-07-23 1995-03-28 Sagami Chem Res Center 抗痴呆薬
JPH07285911A (ja) * 1994-04-20 1995-10-31 New Japan Chem Co Ltd 脂肪族モノカルボン酸組成物
JPH0853351A (ja) * 1994-08-11 1996-02-27 Sagami Chem Res Center 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤
JP3032447B2 (ja) * 1995-04-24 2000-04-17 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JP3084345B2 (ja) 1995-04-26 2000-09-04 小野薬品工業株式会社 光学活性な２−プロピルオクタン酸の製造方法
JPH10298072A (ja) 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
TWI268921B (en) * 1999-02-18 2006-12-21 Ono Pharmaceutical Co A process for preparing (2R)-2-propyloctanoic acid
US6552082B2 (en) * 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
KR100759771B1 (ko) * 2000-07-18 2007-10-04 오노 야꾸힝 고교 가부시키가이샤 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제
JP4706950B2 (ja) 2000-07-18 2011-06-22 小野薬品工業株式会社 アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤
CA2453478A1 (en) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Agent for treatment of cerebral ischemic diseases

Also Published As

Publication number Publication date
US8053599B2 (en) 2011-11-08
EP1669065B1 (en) 2012-07-18
RU2388467C2 (ru) 2010-05-10
MA28142A1 (fr) 2006-09-01
EP1669065A4 (en) 2009-12-16
CN1889942A (zh) 2007-01-03
KR101144553B1 (ko) 2012-05-11
CN1889942B (zh) 2010-12-15
WO2005032536A1 (ja) 2005-04-14
NO20061460L (no) 2006-07-03
ES2390055T3 (es) 2012-11-06
AU2004277826A1 (en) 2005-04-14
IS8430A (is) 2006-04-26
JPWO2005032536A1 (ja) 2006-12-14
CA2540670A1 (en) 2005-04-14
AU2004277826B2 (en) 2010-05-27
KR20060099525A (ko) 2006-09-19
JP4715515B2 (ja) 2011-07-06
ZA200602690B (en) 2007-07-25
NZ546231A (en) 2009-09-25
TW200519080A (en) 2005-06-16
BRPI0415001A (pt) 2006-11-07
RU2006114835A (ru) 2007-11-20
IL174655A0 (en) 2006-08-20
MXPA06003533A (es) 2006-06-08
ECSP066477A (es) 2007-03-29
US20070105956A1 (en) 2007-05-10
EP1669065A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
ECSP066477A (es) Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
AU4583893A (en) Injection and injection kit containing omeprazole and its analogs
KR20120044309A (ko) 적어도 하나의 아드레날린성 화합물을 포함하는 안정화된 조성물
RU2013123457A (ru) Непрерывное введение l-допа, ингибиторов допа-декарбоксилазы, ингибиторов катехол-о-метилтрансферазы и предназначенные для этого композиции
HUP0202749A2 (hu) Levoszimendánt tartalmazó oldat formájú gyógyszerkészítmény
US20190054050A1 (en) Baclofen formulations and methods for making same
EP2047857A4 (en) MEDIUM FOR INJECTION USE WITH AN ANTIBIOTICUM AND THE MEDIUM INJECTING SOLUTION
ECSP066476A (es) Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo
WO2017013677A1 (en) Stable liquid injectable solution of midazolam and pentazocine
RU2013148799A (ru) Дигидропиридины (клевидипин) кратковременного действия для применения в восстановлении после инсульта
KR101153250B1 (ko) 글리시리진 고농도 제제
CA2496121A1 (en) Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy
DOP2005000053A (es) Composicion farmaceutica que comprende acido (2r)-2-propilactanoico como un ingrediente activo
JP2000169378A (ja) 咽頭疾患用組成物
IL97648A0 (en) Stabilized 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide pharmaceutical compositions and methods for the preparation thereof
AR049015A1 (es) Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo
WO2003092767A3 (en) A method for inhibiting platelet aggregation
UA84578C2 (ru) Лекарственное средство, содержащее (2r)-2-пропилоктановую кислоту в качестве активного ингредиента
KR930001302B1 (ko) 시플로플록사신의 주사용 조성물 및 그 제조방법
AR048821A1 (es) "preparacion de infusion que comprende acido (2r)-2-propiloctanoico como un ingrediente activo y recipiente"
JP2002193816A (ja) 微量元素配合製剤
KR20140025369A (ko) 히알루론산 또는 히알루론산염을 포함하는 수용액
JP5922496B2 (ja) 微量元素製剤
UA120764U (uk) Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл"